#Switzerland #ACROBiosystems #Zurich #CytoPak #Wyss Zurich

ACROBiosystems Innovation Day in Zurich

On May 17, 2026, ACROBiosystems held its highly anticipated Innovation Day at the Superlab Suisse in Zürich Schlieren, an inspiring hub for innovation and talent within Switzerland's biotech sector. This event attracted prominent scientists, translational research experts, and industry innovators to discuss groundbreaking developments in biological drugs and translational science, creating an environment rich in discussions and networking opportunities.

Focus on Emerging Technologies

The primary aim of the Innovation Day was to explore emerging technologies, evolving regulatory frameworks, and novel strategies that can expedite the transition from discovery to clinical application. Attendees were treated to a high-quality program featuring advanced development platforms and real-world case studies, encouraging collaboration and fostering innovative thinking.

Prominent speakers included Jenny Ann Prange, PhD, Project Management Head of the Regenerative Medicine Technologies Platform at Wyss Zurich; Lili Qin, PhD, Vice President of Research and Development at ACROBiosystems; Chiara F. Magnani, PhD, Assistant Professor at University Hospital Zurich; and many other key figures.

AI in Protein Engineering

Among the highlights was Dr. Lili Qin's presentation titled "AI-Powered Next-Generation Protein Engineering in CGT." She showcased how ACROBiosystems integrates AI at every phase of protein development—ranging from structure prediction and de novo design to optimization of expression, purification processes, and formulation enhancement. Dr. Qin presented impressive case studies, including an optimized cytokine that achieved a 20-fold increase in expression yield, and a thermostable FGF2 mutant that remains fully active after three days at 37 °C.

Bridging the Gap to Clinical Application

The significance of bridging the gap between early discovery and clinical applications was emphasized by Dr. Jenny Ann Prange, who addressed one of the critical bottlenecks in drug development in her talk titled "Translating Ideas to Reach Those in Need." She detailed how the Wyss Zurich platform combines funding, infrastructure, and translational expertise to support promising projects navigating this intricate pathway.

Dr. Chiara Magnani shared clinical insights into CAR-T cell therapy, presenting findings from a trial involving 36 B-ALL patients who showed an 83% complete remission rate when treated with Sleeping Beauty-derived anti-CD19 CAR-T cells. This presentation highlighted the role of multi-omics analyses in identifying tumor microenvironment immune suppression as a major barrier and introduced a modular AdFITC-CAR T platform that allows for highly customizable targeting.

Innovations in Decentralized Manufacturing

Addressing the complexities in cell therapy production, Dr. Fabien Jammes from Limula proposed solutions for streamlined manufacturing in his talk, "Decentralised Manufacturing of Cell Therapies: How Compact Automation is Changing the Landscape." He introduced the LimONE, a compact platform that integrates bioreactor and centrifuge functionality, presenting proof-of-concept data demonstrating fully automated CAR-T manufacturing within seven days at clinical scale.

Challenges in Enzyme Manufacturing

Dr. Agnese Pisano and Dr. Aaron Debon from INOFEA focused on manufacturing challenges through enzyme immobilization. Their insightful presentation, "Immobilized Enzymes for Smart Biologics Manufacturing Applications in mRNA and ADC Production," discussed a patented technology that boosts enzyme stability and reusability, illustrating two successful case studies.

Conclusion

The Innovation Day at ACROBiosystems was not just a display of scientific advancement, but a testament to the importance of open collaboration in fostering innovation within the biotech sector. Attendees like Giacomo Cattaruzzi, Innovation Director at Muvon Therapeutics AG, expressed their eagerness for such future events, signaling a strong desire for ongoing discussions.

Mike Chen, Chairman and CEO of ACROBiosystems, stated, "We are thrilled to have successfully hosted the ACROBiosystems Innovation Day in Europe, reinforcing our commitment to advancing global biotech innovation. This event will continue to inspire contributions to the industry’s progress."

About ACROBiosystems

Founded in 2010 and publicly listed since 2021, ACROBiosystems is a biotechnology firm dedicated to serving as a cornerstone of the global biopharmaceutical and health industry by providing innovative products and business models. With operations and research facilities in over 15 cities worldwide, ACROBiosystems collaborates with leading pharmaceutical companies like Pfizer, Novartis, and Johnson & Johnson, along with numerous academic institutions.